New drug ARO-HSD tested for fatty liver disease NASH
NCT ID NCT04202354
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This study tested a new drug, ARO-HSD, in 50 healthy volunteers and people with NASH (a serious fatty liver disease). The goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo injection. The trial is now complete, and results will help decide if further testing is warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Auckland Clinical Studies
Grafton, Auckland, 1010, New Zealand
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARO-HSD injection
What this could lead to
If successful, this could point toward a treatment for NASH, a liver disease with no approved therapies.
What could go wrong
This is an early phase 1/2a trial with only 50 participants, so safety and effectiveness are not yet proven. The drug may not work or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.